Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review Publisher

Fallahi MS¹ ; Zerangian N² ; Ghorbani A³ ; Erabi G⁴ ; Shirali M¹ ; Shabani E⁵ ; Rommasi F^{6, 7} ; Najafabadi MM⁸ ; Karbasi S⁸ ; Toutounchian S¹ ; Ahangarsirous R⁹ ; Motaghy A¹⁰ ; Heidari M³ ; Deravi N¹¹

Show Affiliations

1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Health Education and Health Promotion, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
3. Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran
4. Student Research Committee, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
5. Students Research Committee, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
6. Faculty of Life Science and Biotechnology, Shahid Beheshti University, Tehran, Iran
7. Microbiology Research Center(MRC), Pasteur Institute of Iran, Tehran, Iran
8. Department of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
9. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
10. Faculty of Medicine, Riga Stradins University, 16 Dzirciema Street, Riga, LV-1007, Latvia
11. Student Research committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Current Cancer Therapy Reviews Published:2024

Abstract

Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on understanding its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system leading to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underlying mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding. © 2024 Bentham Science Publishers.

Related Docs

View other Related Docs

1. Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials, Clinical Immunology (2021)

2. Research Paper: Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Basic and Clinical Neuroscience (2020)

3. A Concise Review on Cancer Treatment Methods and Delivery Systems, Journal of Drug Delivery Science and Technology (2019)

4. Nivolumab Plus Ipilimumab Combination Therapy in Cancer: Current Evidence to Date, International Immunopharmacology (2023)

5. Comparison of Laboratory Methods for the Clinical Follow up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead, Frontiers in Oncology (2022)

6. Enhanced in Vivo Anti-Tumor Efficacy of Whole Tumor Lysate in Combination With Whole Tumor Cell-Specific Polyclonal Antibody, Research in Pharmaceutical Sciences (2023)

7. Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy, International Immunopharmacology (2022)

8. Efficacy and Safety of Ibrutinib in Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis, DARU, Journal of Pharmaceutical Sciences (2022)

Experts (# of related papers)

View all Related Experts

Mazdak Ganjalikhani Hakemi (2)

Vajihe Akbari (1)

Style	Citing Format
MLA	Fallahi MS, et al.. "Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review." Current Cancer Therapy Reviews, vol. 20, no. 1, 2024, pp. 53-99.
APA	Fallahi MS, Zerangian N, Ghorbani A, Erabi G, Shirali M, Shabani E, Rommasi F, Najafabadi MM, Karbasi S, Toutounchian S, Ahangarsirous R, Motaghy A, Heidari M, Deravi N (2024). Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review. Current Cancer Therapy Reviews, 20(1), 53-99.
Chicago	Fallahi MS, Zerangian N, Ghorbani A, Erabi G, Shirali M, Shabani E, Rommasi F, et al.. "Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review." Current Cancer Therapy Reviews 20, no. 1 (2024): 53-99.
Harvard	Fallahi MS et al. (2024) 'Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review', Current Cancer Therapy Reviews, 20(1), pp. 53-99.
Vancouver	Fallahi MS, Zerangian N, Ghorbani A, Erabi G, Shirali M, Shabani E, et al.. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review. Current Cancer Therapy Reviews. 2024;20(1):53-99.
BibTex	@article{ author = {Fallahi MS and Zerangian N and Ghorbani A and Erabi G and Shirali M and Shabani E and Rommasi F and Najafabadi MM and Karbasi S and Toutounchian S and Ahangarsirous R and Motaghy A and Heidari M and Deravi N}, title = {Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review}, journal = {Current Cancer Therapy Reviews}, volume = {20}, number = {1}, pages = {53-99}, year = {2024} }
RIS	TY - JOUR AU - Fallahi MS AU - Zerangian N AU - Ghorbani A AU - Erabi G AU - Shirali M AU - Shabani E AU - Rommasi F AU - Najafabadi MM AU - Karbasi S AU - Toutounchian S AU - Ahangarsirous R AU - Motaghy A AU - Heidari M AU - Deravi N TI - Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review JO - Current Cancer Therapy Reviews VL - 20 IS - 1 SP - 53 EP - 99 PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract